NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Biomea Fusion, Inc. (BMEA) Stock Analysis

Biomea Fusion, Inc. (BMEA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BMEA

$2.03

+$0.12 (+6.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BMEA with… →

BMEA Key Statistics

As of Sep 4, 2026
Trading
Open
$1.90
Previous Close
$1.91
Day's Range
1.89–2.05
52-Week Range
0.87–2.99
Volume
3.29M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.24
Valuation
Market Cap
$146.77M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.19
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$61.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.30M
1-Year Return
+10.93%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BMEA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+63.71%
2025−68.04%
2024−73.28%
2023+72.24%
2022+13.15%
2021 (partial year)−59.95%

As of September 4, 2026.

BMEA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$61.80M—
2024$0.00−$138.43M—
2023$0.00−$117.26M—
2022$0.00−$81.83M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$81.31M−$61.80M—
2024$0.00—−$144.07M−$138.43M—
2023$0.00—−$126.14M−$117.26M—
2022$0.00—−$83.63M−$81.83M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BMEA Valuation vs Biotechnology Median

Median of 656 stocks
MetricBMEABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Biomea Fusion, Inc. (BMEA) is capitalised at $146.77M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 37.

The 52-week range on file runs from $0.87 to $2.99. The most recent close on file for BMEA is $2.03, dated September 4, 2026. That is +$0.12 (+6.28%) against the previous close. The latest close sits 132.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $61.80M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +10.93%. Across 5 years the annualized return works out at −31.67%. The reported beta is −0.24. Daily returns over the trailing 5 years annualize to a volatility of 110.55%.

Growth & Income

No dividend is on file for BMEA.

So far in 2026 the price is +63.71%. The strongest complete calendar year on file is 2023 at +72.24%; the weakest is 2024 at −73.28%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Biomea Fusion, Inc. (BMEA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biomea Fusion, Inc. BMEA $146.77M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Biomea Fusion, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Visit website →